About us - Viktoriya and Oksana LLC

If you want to chat or are looking for the next step in your healing journey you can e-mail us at [email protected]

Because we’re an international company focused on providing the best program for rapid reversal of autoimmunity, we have clients and employees located all around the globe, with two company office headquarters located in the United States (Michigan and Florida).

Viktoriya and Oksana LLC and their team work with their clients globally and they’ve been able to help hundreds of people from all over the globe recover their health all in the comfort of their own home.

Born in Ukraine	• Born in Ukraine. • We grew up in poverty living in a 250 sq ft apartment with a family of five. • Our mother was a midwife in Ukraine. • As kids, both my sister and I suffered with thyroid issues and ear infections.
Our father had a heart attack at the age of 35 due to financial and work stress	• Our dad worked 18-hour days with very little pay as a software engineer. • In his early 30s, he was mugged and beaten at the subway. • At 35, our father had a heart attack. Ambulance in Ukraine never came on time and my mom (being a midwife) had to give him an epinephrine to save his life. • When our father was in his 40’s, an opportunity came….He was offered a job in the United States. • In his 40’s, he moved to USA with only $300 to work as a engineer; he had to learn to drive a car and speak English. • Our father washed toilets at the restaurant to make extra money to support his family.
In our teens, we suffered with cystic acne, teeth infections, hair loss, migraines, tonsilitis, hormnal issues	• In our early teens, both my sister, mom, brother moved to USA to live with our father. • At the age of 18, we started experiencing hair loss, allergies, teeth infections, migraines, tonsilitis, hormonal issues, weight gain. • We both went to naturopathic doctors and functional doctors and spend $300 per months on herbs and supplements, tried juicing, fasting but still had symptoms.
In our early 20s, Oksana started work in immunology and has published dozens of peer-reviewed publications in scientific journals	• In early 20’s, Oksana started working as an immunology scientist after graduating from university. • Over the course of several years, Oksana has worked 18 hours days and became a peer reviewed published immunology researcher. • Oksana has dozens of publications in peer-reviewed scientific journals and presented at national and international research conferences. • While working full time, we took a loan to invest into continued education to learn about how every food affects immunity, inflammation and cellular repair and applied the knowledge on ourselves. • In our early 20’s we have applied our personal research and studies on ourselves, and all our symptoms were gone and to this year, we are still symptom free and none of our symptoms have re-appeared and all of our labs are excellent. • In our mid 20’s, we started working locally with people to help them with their autoimmune health and we had incredible success rate helping people locally. • Our research professor had arthritis and we helped him become symptom free by optimizing his nutrition for rapid immune and cellular repair and he has been symptom free already for 7 years (plus he is off his medications and does not take supplements).
In our late 20’s hired mentors and attended coaching events to help us optimize our rapid autoimmune disease reversal program	• Since 2013, we invested into mentorships, conferences (both clinical and research a well as nutritional) to become experts in disease reversal. • We created our program so anyone in the world can participate and get help with their healing all in the comfort of their own home! We have worked with clients globally, including from USA, India, Canada, Italy, France, Mexico, Spain, Russia, Dominical Republic, Hungary, Australia, and even South Africa. • We lived in 525 square foot studio apartment for several years while paying for research conferences and expenses that went into running our programs! • We have designed a rapid disease reversal program where anyone in the world can participate and get results and know what they need to do to take next steps without us and remain disease free.
We have 11 years of experience and helped hundreds of clients rapidly reverse all types of autoimmune diseases. This lifesaving program to reverse autoimmune symptoms and labs as fast as 40 days may sound simple, but it took us 11 years and half a million in education plus a decade of experience to make it THAT simple.	We trademarked our program, VIKTORIYA AND OKSANA’S RAPID IMMUNOCELLULAR REPAIR ® program because it’s unique to us since every client you see on our website got those results after working with us that they couldn’t get before working with functional doctors, chiropractors, and nutritionists. • When working with clients 1-1, we have found that it took 3-4 weeks for majority of our clients become symptom free. • 80% of our clients see rapid results in their health in the first 40 days of us working together and some of them are even already symptom free, while others make progress in their symptoms and labs. • As immunology scientists, we dedicated our life helping others as much as we possibly can so we base all our recommendations on ACTUAL and CONSISTENT RESULTS in real people, never based on things we read or assume. • Many of our clients say that our program is “life changing” or they “got the most help from us in a couple of weeks than they ever got from their doctor in 10 years” “you are looking at 2 women who will cure cancer someday.” • We have REVERSED hundreds diseases for people and we have SEEN and CONQUERED thousands of variety of ISSUES, CHALLENGES in people within specific disease and state of illness to create a step by step process that helps every inflammatory disease. Our program (s) not only rapidly reverses every inflammatory chronic illness but also reverses aging. 1. Improve your immunity… 2. Improve the body’s ability to fight infections… 3. Reverse damage from long-term chronic inflammatory diseases… 4. Reversing aging, improve energy, reverse diabetes and high blood pressure and increases athletic performance in athletics… 5. Faster recovery and healing after surgery….

We create a disease reversal program for you based on your disease, symptoms, and based on OUR proven and science-based process for reversing chronic inflammatory disease and repairing your immune system.

In our program, we repair the immune system, so it goes back to normal function and heal the damage that has been done by the disease. If you still test positive for an autoimmune disease, you still have an autoimmune disease and not FULLY healed. Our clients have reversed symptoms and autoimmune markers as soon as in 30 days because they are getting specific instructions and feedback DAILY based on how their body responds and based on the DECADE of our experience helping people GLOBALLY become disease free. (typical results our clients get in 40 days here).

You get daily feedback on your progress and questions answered every day (including weekends) AND we make REAL TIME adjustments to your recovery program based on the RESULTS you’re getting.

We teach you what you have to do during each stage of your healing and provide education through it which takes all the guesswork out of the equation. You never have to guess anymore “am I doing this right or am I doing enough?”

If you are not getting results like our clients do in 40 days, it is time to work closely with us. Our program is not just for some people – it’s optimal for the immune system and it effectively and reproducibly reverses autoimmune. If you are not doing well, we need to solve the issues and change aspects of your nutrition until you get the results you are seeking.

Hundreds of testimonials of our clients shared on social media and our clients didn’t just become better, they achieved full disease reversal and many of them no longer needed medications.

Our program(s) was NOT designed based on the mold of other autoimmune protocols or authors/doctors but from our understanding of the immune system and through repeated EXPERIENCE.

Our program(s) is STEP by STEP daily guidance where we will show you EXACTLY what to do in every stage of healing to keep you making progress and moving towards your ultimate goal.

Their program(s) and our client results cannot be achieved or done without our supervision and guidance.

Click HERE to schedule your chat.

HONORS AND AWARDS

2006 Co-founder of the Circle K International, Wayne State University Chapter

2006-2007 Outstanding Student Service Award (Michigan Campus Compact)

2007-2008 Outstanding Student Service Award (Michigan Campus Compact)

2010 Outstanding Achievement Award (Project Volunteer, Wayne State University)

2012 7th Annual David Fromm Research Award Recipient, First Price, WSUSOM

2013 8th Annual David Fromm Research Award Recipient, Third Price, WSUSOM

2014 2016 Professional Development Scholarship, Golden Key International Honour Society

10th Annual David Fromm Research Award Recipient, First Price, WSUSOM

RESEARCH EXPERIENCE

04/2008 – 01/2009

Department of Biology, Wayne State University, MI

Determined the effect of ISWI1 gene deletion on MET16 transcription
receptor: Dr. Athar Ansari

01/2011 – Present

Researcher, Department of Surgery, Wayne State University School of Medicine, MI

Produced and manufactured recombinant self-complementary Adeno-Associated Viral (scAAV) vector encoding (a) Pre-miR-101 (b) Pre-miR-26a (c) MAGE-A3 and NY-ESO-1 (d) Green Fluorescent Protein to be used in gene therapy for pancreatic and ovarian cancers
Generated and produced novel triple mutant AAV-6 capsid vector
Performed dendritic cell-based immunotherapy with Cell Penetrating Domains (CPD) and rAAV-MAGE-A3, rAAV-ESO-1 of ovarian and pancreatic cancer cells
Determined the effect of miR-101 and miR-26a re-expression on pancreatic and ovarian cancers

Skills and Techniques

Gene profile analysis, statistical analysis of microarray data
STD-PAGE and Western Blotting
In-situ hybridization of tissue samples
In vitro cell proliferation, colony formation, cell migration, cell invasion, wound-healing, chemosensitivity, apoptosis, and drug efflux assays
Chromatin immunoprecipitation
Real-Time (quantitative) PCR, mammalian cell culture, immunohistochemistry
Dendritic Cell isolation and purification, flow cytometry
Generation, purification, quantification of Adeno-Associated Virus (AAV)
Dendritic Cell transduction with AAV
Cytotoxic T Cell Lymphocyte (CTL) generation
Isolation of peripheral blood mononuclear cells
RNA and DNA isolation, purification, transformation, transduction, transfection
Intraperitoneal and intravenous injection of rAAV and analysis of tumor tissue samples in murine animal models
Writing abstracts, manuscripts, and grant proposals

Oral presentations at national & international conferences and meetings:

Central Surgical Association, March 8th, Palm Harbor, FL 2019
Academic Surgical Congress, February 5th, Houston, TX 2019
American College of Surgeons, Boston, MA 2018: Oksana was 1 of 8 nominated authors (selected out of 500 authors)
Clinical Application of CAR T Cells, New York, NY 2017
American College of Surgeons (ACS), San Diego, CA 2017
Central Surgical Association (CSA), Chicago, IL 2017
Central Surgical Association (CSA), Montreal, Quebec 2016
American College of Surgeons (ACS) Washington, DC 2016
David Fromm Research Award, January 28th, 2016 (WON FIRST PLACE; awarded a David Fromm research scholarship)
American College of Surgeons (ACS), Chicago, IL 2015
Central Surgical Association (CSA), Chicago, IL 2015
Academic Surgical Congress (ASC), Las Vegas, NV 2015
Central Surgical Association (CSA), Indianapolis, IN 2014
Academic Surgical Congress (ASC), San Diego, CA 2014
American College of Surgeons (ACS), Washington, DC 2013
Academic Surgical Congress (ASC), New Orleans, LA 2013
David Fromm Research Day, January 2013 (Won first place and a David Fromm research scholarship)
American College of Surgeons (ACS), Chicago, IL 2012
Academic Surgical Congress (ACS), Las Vegas, NV 2012
Peer-Reviewed Publications:
Click here to see our peer-reviewed publications in scientific journals on pubmed
and many others.

Oksana’s second author, Book Publication on HIV research, 2011:
https://www.intechopen.com/books/recent-translational-research-in-hiv-aids/crippling-of-hiv-at-multiple-stages-with-recombinant-adeno-associated-viral-mediated-rna-interferenc

AWARDS AND ACCOMPLISHMENTS

7 th Annual David Fromm Research Award Recipient, 2013
8 th Annual David Fromm Research Award Recipient, 2014
Outstanding Achievement Award (Project Volunteer, Wayne State University), 2008
Outstanding Student Service Award (Michigan Campus Compact), 2009
Professional Development Scholarship, Golden Key International Honor Society, 2008
Undergraduate Tuition Scholarship for Portfolio Gold Metals and Golden Key Award Scholarships 2004

PUBLICATIONS

Batchu RB, Gruzdyn OV, Kolli BK, Tavva PS, Dachepalli R, Inhibition of IL-10 in the tumor microenvironment potentiates mesothelin-chimeric antigen receptor NK-92MI-mediated killing of ovarian cancer cells. J Am Coll Surg. 2020 Oct; 231(4): E54-E55.
Batchu RB, Gruzdyn OV. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Surgery. 2019 Oct;166: 503–508. PMID: 31416604.
Batchu RB, Gruzdyn OV. Inhibition of IL-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery. 2018 Mar; 163:627-632. PMID: 29336814.
Batchu RB, Gruzdyn OV. Inhibition of IL-10 augments mesothelin chimeric antigen receptor T cell activity in epithelial ovarian cancer. J Am Coll Surg. 227(4):e215-e216. 2018.
Batchu RB, Gruzdyn OV, Qazi AM. Pancreatic cancer cell lysis by cell penetrating peptide-MAGE-A3-induced cytotoxic T lymphocytes. JAMA Surg. 151: 1086-1088. PMID: 27851862. 2016.
Batchu RB, Qazi AM, Gruzdyn OV, Kaur J, Mahmud EM. Inhibition of epithelial ovarian cancer (EOC)-induced microenvironment can restore dendritic cell (DC) activation and migration. Journal of the American College of Surgeons, Volume 221, Issue 4, Supplement 2, October 2015, Page e33, ISSN 1072-7515, http://dx.doi.org/10.1016/j.jamcollsurg.2015.08.384.
Batchu RB, Gruzdyn OV, Qazi AM, Kaur J. Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. Surgery 158: 981-87, 2015.
Ramesh B. Batchu, Oksana Gruzdyn. MAGE-A3 with Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine. JAMA Surgery, 2014; 149:451-457. PMID: 24671426
Ramesh B. Batchu, Oksana Gruzdyn. Dendritic cell based immunotherapy of cancer with cell penetrating domains. Indian Journal of Surgical Oncology, 2014; 5:3-4. PMID: 24669158
Batchu RB, Gruzdyn OV. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways. Pharmaceuticals, 2014; 7:46-57. PMID: 24451403
Batchu RB, Gruzdyn OV. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine, 2014; 32:938-43. PMID: 24406390
R.B. Batchu, O. Gruzdyn. Negative Regulation of Mutant p53 by MicroRNA-101 (miR-101) in Pancreatic Ductal Adenocarcinoma (PDAC). Journal of Surgical Research, 2013; Volume 179, Issue 2, 341
RB Batchu, AM Qazi, OV Gruzdyn. EZH2-shRNA Mediated Up-regulation of p21waf1/cip1 and its Transcriptional Enhancers with Concomitant Down-modulation of Mutant p53 in Pancreatic Ductal Adenocarcinoma. Surgery, 2013; 154:739-46. PMID: 24074410
A, Qazi AM, Gruzdyn OV. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Letters, 2013; 336:53-60. PMID: 23603558
Aamer M Qazi, Oksana Gruzdyn. Restoration of E-Cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery, 2012; 152:704-11. PMID: 22943841
INVITED LECTURES/ORAL PRESENTATIONS: NATIONAL/INTERNATIONAL
Inhibition of TGF-β in the tumor microenvironment potentiates MSLN-CA NK-92MI-mediated killing of pancreatic cancer cells. Pittsburgh, PA, 2020 (Canceled due to COVID-19), April 2020
Inhibition of IL-10 in the tumor microenvironment potentiates MSLN-CAR NK-92MI-mediated killing of pancreatic cancer cells. Central Surgical Association (CSA), virtual meeting, Milwaukee, WI, 2020 (Virtual meeting), June 2020
Engineering IL-2 secreting MSLN-CAR NK-92 cell line can resist inhibition by pancreatic tumor microenvironment. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Seattle, WA, April 2019
Engraftment of MSLN-CAR using a hybrid sleeping beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. National Research Week. Presenter, Gruzdyn, OV. Mentor, Batchu RB, April 2019
MSLN-CAR with sleeping beauty and minicircle DNA engrafted NK-92MI cells for the treatment pancreatic cancer, CSA. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Palm Harbor, FL., March 2019
Sleeping beauty and minicircle design of MSLN-CAR enhances cytotoxicity in pancreatic cancer. Academic Surgical Congress (ASC). Presenter, Gruzdyn, OV. Mentor, Batchu RB. Houston, TX. , February 2019
Inhibition of IL-10 can restore mesothelin chimeric antigen receptor (CAR) T cell activity in ovarian cancer. One of the 8 e-Posters of Exceptional Merit (ePOEM) presentation out of 500 abstracts, ACS, Clinical Congress. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Boston, MA., October 2018
MSLN-CAR-Mediated Therapy for Ovarian Cancer, ACS, Clinical Congress. Presenter, Gruzdyn, OV. Mentor, Batchu RB. San Diego, CA. , October 2017
CAR-mediated therapy for pancreatic cancer. Podium Presenter: Gruzdyn OV, Mentor: Batchu RB., August 2017
Efficient Lysis of Pancreatic Cancer Cells by MAGE-A3-Induced Cytotoxic T Lymphocytes (CTLs) using Cell-Penetrating Peptides (CPPs). Oral Presentation, 40th Annual Meeting, Virginia Beach, April 10-12, 2016
Pancreatic Cancer-induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-kB. Oral Presentation, Central Surgical Association annual meeting (CSA), Montreal, QC, March 10-12, 2016
Inhibition of Epithelial Ovarian Cancer (EOC)-Induced Microenvironment can Restore Dendritic Cell (DC) Activation and Migration. Oral Presentation, American College of Surgeons (ACS) Clinical Congress, Chicago, IL, October, 2015
IL-10 and TGF-B Blockade Reverses the Inhibitory Effects of Pancreatic Carcinoma on Dendritic Cell Activation and Migration. Oral Presentation, 39th Annual Meeting, Miami, FL, May 2-5, 2015
Enhanced Ser9 phosphorylation of p53 by miR-26a leading to growth inhibition of Pancreatic Ductal Adenocarcinoma. Oral Presentation, Central Surgical Association annual meeting (CSA), Chicago, IL, March 5-7, 2015
Enhanced Chemosensitivity of Ovarian Cancer Cells via EZH1 Knockdown and Down-regulation of mTOR. Oral Presentation, 10th Annual Academic Surgical Congress (ASC), Las Vegas, NV, February 5, 2015
MicroRNA-101 (miR-101) down-regulates mutant p53 in Epithelial Ovarian Cancer (EOC). Oral Presentation, 38th Annual Meeting, New Haven, CT, April, 6, 2014
Enforced Expression of microRNA-26a via Adeno-Associated Viral transduction inhibits growth of Epithelial Ovarian Cancer. Oral Presentation, Central Surgical Association annual meeting (CSA), Indianapolis, IN, March 6, 2014
Novel AAV-DJ Capsid Tyrosine Mutants with Enhanced Transgene Expression in a Pancreatic Cancer Cell Line. Oral Presentation, 9th Annual Academic Surgical Congress (ASC), San Diego, CA, February 4, 2014.
Enhancer of Zeste Homolog 2 (EZH2) Silencing Down-modulates Mutant p53 with Increased Chemosensitivity in Epithelial Ovarian Cancer (EOC). Oral Presentation, American College of Surgeons (ACS) Clinical Congress, Washington, DC, October 7, 2013
Enhanced dendritic cell permeability of genetically engineered MAGE-A3 with cell penetrating domain (CPD) for the generation of an efficient therapeutic cancer vaccine. Oral Presentation, 37th Annual Surgical Symposium, Milwaukee, WI, April, 21-23, 2013
EZH2-shRNA mediated up-regulation of p21WAF1/CIP1 and its transcriptional enhancers with concomitant down-modulation of mutant p53 in pancreatic ductal adeno-carcinoma (PDAC). Central Surgical Association (CSA) Omni Amelia Island Plantation – Amelia Island, FL, March 14-16, 2013
Negative Regulation Of Mutant P53 By MicroRNA-101 (miR-101) In Pancreatic Ductal Adenocarcinoma (PDAC). Oral Presentation, 8th Annual Academic Surgical Congress (ASC), New Orleans, LA, February 5, 2013
Inhibition of mammalian target of rapamycin (MTOR) signaling by microrna-101 (mir-101) results in enhanced chemosensitivity of epithelial ovarian cancer (EOC) cells. 36th Annual Meeting, April 1-3, 2012
Restoration Of E-Cadherin (E-Cad) Expression In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With MicroRNA-101 (MiR-101). Central Surgical Association, Annual Meeting. March 1-3, Madison, Wisconsin, 2012
Novel Tyrosine Mutant Recombinant Adeno-associated Viral (rAAV) Transduction of Dendritic Cells (DCs) as a Step Towards Therapeutic Vaccination in Multiple Myeloma (MM). Oral Presentation, American College of Surgeons, 98th Annual Clinical Congress, Sep 30 – Oct 4, Chicago, IL, 2012
MicroRNA-101 (miR-101) Enhances Chemosensitivity Of Pancreatic Ductal Adenocarcinoma (PDAC) Cells By Inhibition Of MTOR Signaling Via PRAS40. 7th Annual Academic Surgical Congress – February 14-16, Las Vegas, NV, 2012
MicroRNA-101 (miR-101) Promotes Expression Of E-cadherin (E-Cad) By Relieving Epigenetic Repression In Epithelial Ovarian Cancer (EOC). Oral Presentation, 7th Annual Academic Surgical Congress – February 14-16, Las Vegas, Nevada, 2012
INVITED LECTURES/ORAL PRESENTATIONS: LOCAL
Efficient Lysis of Pancreatic Cancer Cells by MAGE-A3-Induced Cytotoxic T Lymphocytes Using Cell-Penetrating Peptides. Oral Presentation. 10th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, April 6, 2016
Pancreatic Cancer-induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-kB. Oral Presentation. Detroit, MI, March 25th, 2016 and again at 10th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, April 6, 2016
Efficient Lysis of Epithelial Ovarian Cancer (EOC) by MAGE-A-3-Induced Cytotoxic T Lymphocytes Using rAAV-6 Capsid Mutant Vector. Oral Presentation. Detroit, MI, May 2015
Enhanced Chemosensitivity of Ovarian Cancer via EZH2 Knockdown and Downregulation of mTOR. Oral presentation, 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
MicroRNA-101 Down-regulates Mutant p53 in Epithelial Ovarian Cancer. 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
Enhanced ser9 phosphorylation of p53 by miR-26a leading to growth inhibition of pancreatic ductal adenocarcinoma. 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
rAAV-miR-101 Mediated Inhibition of EOC: Activation of p53-p21waf1/cip1 pathway. Oral Presentation, Detroit, MI, May, 2014
Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine. Oral Presentation, 8th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI. October, 2013 (David Fromm Award Recipient)
Enhancer of zeste homolog 2 (EZH2) silencing down-modulates mutant p53 with increased chemosensitivity in epithelial ovarian cancer (EOC). Oral Presentation, 8th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI. October, 2013 (David Fromm Award Recipient)
Novel Tyrosine Mutant Recombinant Adeno-associated Viral Transduction of Dendritic Cells as a Step Towards Therapeutic Vaccination in Multiple Myeloma. Oral Presentation, 7th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2012 (David Fromm Award Recipient)
Restoration Of E-Cadherin Expression In Pancreatic Ductal Adenocarcinoma Treated With MicroRNA-101. Oral Presentation, 6th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2011
MicroRNA-101 in Cancer: Targets and Therapy. Seminars in Medicine, Medical Education Lecture Series. Detroit, MI, October, 2011.
Inhibition of mTOR Signaling by MicroRNA-101 Results in Enhanced Chemosensitivity of Epithelial Ovarian Cancer Cells. 6th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2011
Re-expressioin of microRNA-101 inhibits cell proliferation, metastasis and growth of pancreatic tumor xenografts. GI Cancer Research seminar series, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI April 29, 2011
ABSTRACTS IN CONFERENCES
IL-10 and TGF-B Blockade Reverses the Inhibitory Effects of Pancreatic Carcinoma on Dendritic Cell Activation and Migration. Oral Presentation, 39th Annual Meeting, Miami, FL, May 2-5, 2015
Enhanced Ser9 Phosphorylation of P53 By miR-26a Leading to Growth Inhibition of Pancreatic Ductal Adenocarcinoma, R. B. Batchu et al. Abstract 18, 72nd Annual Meeting of the Central Surgical Association. Chicago, IL. March 5-7th, 2015
Enhanced Chemosensitivity of Ovarian Cancer Cells via EZH2 Knockdown and Down-regulation of mTOR. 10th Annual Academic Surgical Congress, Las Vegas, NV, February 5, 2015
Dendritic cell based immunotherapy with MAGE-A3 using Adeno-associated virus as delivery vehicle for ovarian cancer. Department of Microbiology. Rosalind Franklin University of Medicine and Science, Chicago, IL. June 3rd, 2014
MicroRNA-101 (miR-101) Down-regulates Mutant p53 in Epithelial Ovarian Cancer (EOC). New Haven, CT, April 6, 2014
Enforced expression of microRNA-26a via adeno-associated viral transduction inhibits growth of epithelial ovarian cancer. Central Surgical Association, Indianapolis, IN. March 6-8, 2014
AAV-DJ Capsid tyrosine mutants with enhanced transgene expression in a pancreatic Cancer Cell Line. 9th Annual Academic Surgical Congress. February 4-6, San Diego, CA, 2014
Enhancer of Zeste homolog 2 silencing down-modulates mutant p53 with increased chemosensitivity in epithelial ovarian cancer. Journal of American College of Surgeons. 217: S138-S139, 2013
Negative Regulation of Mutant P53 by MicroRNA-101 (miR-101) in Pancreatic Ductal Adenocarcinoma (PDAC). Journal of Surgical Research. 179:341, 2013
MicroRNA-101 (miR-101) Promotes Expression of E-cadherin (E-Cad) By Relieving Epigenetic Repression in Epithelial Ovarian Cancer (EOC). Journal of Surgical Research. 172: 313-314, 2012
MicroRNA-101 (miR-101) Enhances Chemosensitivity of Pancreatic Ductal Adenocarcinoma (PDAC) Cells By Inhibition of MTOR Signaling Via PRAS40. Journal of Surgical Research. 172: 233, 2012
Novel tyrosine mutant recombinant adeno-associated viral (rAAV) transduction of dendritic cells (DCs) as a step towards therapeutic vaccination in multiple myeloma (MM). Journal of American College of Surgeons. 215: S94, 2012
POSTER PRESENTATIONS
Pancreatic Cancer-Induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-κB. Detroit, MI, May, 2016
Enhanced Phosphorylation of p53 by miR-26a Leading to Growth Inhibition of Pancreatic Cancer. Detroit, MI, May, 2015
MicroRNA-101 Down-regulates Mutant p53 in Epithelial Ovarian Cancer. Detroit, Michigan, May, 2014
MAGE-A3 with cell penetrating domain as an efficient therapeutic cancer vaccine. Detroit, Michigan, May, 2013
Enforced expression of MicroRNA-26a via Adeno-Associated Viral transduction inhibits growth of epithelial ovarian cancer. Wayne State University School of Medicine Graduate Student Research Day, Detroit, Michigan, May, 2013
Inhibition of mammalian target of rapamycin (mTOR) signaling by microRNA-101 (miR-101) results in enhanced chemosensitivity of epithelial ovarian cancer (EOC) cells. Detroit, Michigan, May 2012
MicroRNA-101 (miR-101) Promotes Expression of E-cadherin (E-Cad) By Relieving Epigenetic Repression in Epithelial Ovarian Cancer (EOC). Detroit, Michigan, May 2012
Novel Tyrosine Mutant Recombinant Adeno-associated Viral (rAAV) Vector Carrying MAGE-A3 Transduction of Dendritic Cells (DCs) as a Step Towards Therapeutic Vaccination in Multiple Myeloma (MM). Detroit, Michigan, May 2012
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mTOR. Detroit, MI, May 2011
Re-expression of CDKN1A (p21Waf1/Cip1) by microRNA-101: Inhibition of in vitro cell proliferation, metastasis and growth of pancreatic tumor xenografts. Detroit, Michigan, May 2011

Click HERE to schedule your chat.